Placental peptides as markers of gestational disease

Reproduction

Volumn 123, Issue 4, 2002, Pages 487-495

  Page, Nigel M ^a   Kemp, C Fred ^a   Butlin, David J ^a   Lowry, Philip J ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; PLACENTA PROTEIN;

CHROMOSOME DISORDER; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; GENOMICS; HUMAN; INTRAUTERINE GROWTH RETARDATION; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREGNANCY DISORDER; PREMATURE LABOR; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEOMICS; RELIABILITY; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TROPHOBLASTIC DISEASE;

MAMMALIA;

EID: 0036215624     PISSN: 14701626     EISSN: None     Source Type: Journal    
DOI: 10.1530/rep.0.1230487     Document Type: Review

References (73)

1. Expression of the insulin-like growth factors and their receptors in term placentas: A comparison between normal and IUGR births
2. Longitudinal analysis of maternal plasma leptin concentrations during normal pregnancy and pre-eclampsia
3. Fibroblast growth factor-2 and fibroblast growth factor receptor-1 mRNA expression and peptide localization in placenta from normal and diabetic pregnancies
4. The value of elevated second-trimester beta-human chorionic gonadotropin in predicting development of pre-eclampsia
5. Rise and fall of Western diseases
6. Insulin-like growth factor 1 in controls and growth-retarded fetuses
7. The turning point in genome research
8. Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy
9. Plasma corticotrophin-releasing hormone concentrations during pregnancy and parturition
10. Fetal plasma leptin concentrations: Relationship with different intrauterine growth patterns from 19 weeks to term
11. Expression of insulin-like growth factor in the placenta of intrauterine growth-retarded human fetuses
12. Amniotic fluid endothelin-1 levels are increased in pregnancy-induced hypertension and intrauterine growth retardation
13. Adrenomedullin, a new vasoactive peptide, is increased in preeclampsia
14. Neuropeptide Y and nitrite levels in pre-eclamptic and normotensive gravid women
15. Alpha subunit and human chorionic gonadotropin in normal pregnancy and gestational trophoblastic disease
16. A study of early pregnancy factor activity in the sera of women with trophoblastic tumor
17. Insulin-like growth factors and their binding proteins in the term and preterm human fetus and neonate with normal and extremes of intrauterine growth
18. Increased AFP in maternal serum as an indication for invasive diagnosis
19. Elevated endothelin levels are associated with increased placental resistance
20. Decreased circulating adrenomedullin in pre-eclampsia
21. Secretion of the vasoactive peptides, endothelin, and parathyroid hormone-related peptide, by decidual explants from pregnancies complicated by intrauterine growth restriction
22. Leptin in pregnancy
23. Isolation of cDNAs encoding four mouse FGF family members and characterization of their expression patterns during embryogenesis
24. Fibroblast growth factor 2 is elevated in term maternal and cord serum and amniotic fluid in pregnancies complicated by diabetes: Relationship to fetal and placental size
25. Growth factors and the regulation of fetal growth
26. Corticotrophin-releasing hormone and CRH-binding protein. Differences between patients at risk for preterm birth and hypertension
27. Epidermal growth factor in urine of nonpregnant women and pregnant women throughout pregnancy and at delivery
28. Increased production of tumor necrosis factor-alpha TNF-alpha by IUGR human placentae
29. Maternal insulin-like growth factor binding protein-1, body mass index, and fetal growth
30. Increased plasma levels of vasoactive intestinal polypeptide in pre-eclampsia
31. Applications of biochip and microarray systems in pharmacogenomics
32. Ontogeny of leptin in human fetuses and newborns: Effect of intrauterine growth retardation on serum leptin concentrations
33. Expression of epidermal growth factor in gestational trophoblastic disease (GTD)
34. Increased plasma leptin in gestational diabetes
35. Increased concentrations of plasma neuropeptide Y in patients with eclampsia and pre-eclampsia
36. Fetal angiotensin II levels and vascular (type 1) angiotensin receptors in pregnancies complicated by intrauterine growth retardation
37. Serum insulin-like growth factors and insulin-like growth factor binding proteins in the human fetus. Relationships with growth in normal subjects and in subjects with intrauterine growth retardation
38. Macrosomia associated with maternal serum insulin-like growth factor-I and -II in diabetic pregnancy
39. Mid-trimester beta-hCG levels incorporated in a multifactorial model for the prediction of severe pre-eclampsia
40. Growth factors and intrauterine growth retardation II. Serum growth hormone, insulin-like growth factor (IGF) I, and IGF-binding protein 3 levels in children with intrauterine growth retardation compared with Prospective study from birth to two years of age
41. Overexpression of placental leptin in diabetic pregnancy: A critical role for insulin
42. Prenatal leptin production: Evidence that adipose tissue produces leptin
43. Epidermal growth factor in maternal urine - A predictor of intrauterine growth restriction?
44. Corticotropin releasing hormone-binding protein (CRH-BP): Plasma levels decrease during the third trimester of normal human pregnancy
45. A specific carrier substance for human corticotrophin releasing factor in late gestational maternal plasma which could mask the ACTH-releasing activity
46. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r)
47. What is bioinformatics? A proposed definition and overview of the field
48. The contribution of low birth weight to infant mortality and childhood morbidity
49. Corticotropin-releasing hormone in human pregnancy and parturition
50. Predicting risk of preterm delivery by second-trimester measurement of maternal plasma corticotropin-releasing hormone and alpha-fetoprotein concentrations
51. A placental clock controlling the length of human pregnancy
52. Activin A and inhibin A as possible endocrine markers for preeclampsia
53. Early detection of persistent trophoblastic tumour by serum human chorionic gonadotrophin monitoring after molar pregnancy
54. Serum leptin levels and the severity of pre-eclampsia
55. Insulin-like growth factor 1 in fetal serum obtained by cordocentesis is correlated with intrauterine growth retardation
56. Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia
57. The development of a genetic profile of placental gene expression during the first trimester of pregnancy: A potential tool for identifying novel secreted markers
58. Functional genomics conference: From identifying proteins to faster drug discovery
59. Leptin concentrations in cord blood in normal newborn infants and offspring of diabetic mothers
60. The origin of endothelin-1 in patients with severe preeclampsia
61. Plasma endothelin-1 and mean arterial pressure in the prediction of pre-eclampsia
62. Endothelin-1 in fetoplacental tissues from normotensive pregnant women and women with pre-eclampsia
63. Placental IGF-1 in severe intrauterine growth retardation
64. Validity in nulliparas of increased beta-human chorionic gonadotrophin at mid-term for predicting pregnancy-induced hypertension complicated with proteinuria and intrauterine growth retardation
65. Cord blood leptin concentrations in relation to intrauterine growth
66. Alterations of maternal and fetal leptin concentrations in hypertensive disorders of pregnancy
67. Maternal serum screening for Down's syndrome in early pregnancy
68. Prenatal screening for Down's syndrome using inhibin-A as a serum marker
69. The concentration of insulin-like growth factor-1 and insulin-like growth factor-binding protein-1 in human umbilical cord serum at delivery: Relation to fetal weight
70. Cord blood insulin to assess the quality of treatment in diabetic pregnancies
71. Association of human corticotropin-releasing hormone to its binding protein in blood may trigger clearance of the complex
72. The relation between the levels of serum lipid peroxide, superoxide dismutase and atrial natriuretic peptide in placenta, umbilical cord vein and intrauterine growth retardation in pregnancy induced hypertension
73. Peripartal temporal course of endothelin 1, angiotensin II, and atrial natriuretic peptide in pre-eclampsia and normotensive pregnancy